Disclosed herein is a particle delivery system comprising electrospun nanofiber comprised of coaxial fiber with a microfluidic core. Iron-doped apatite nanoparticles (IDANPs) have demonstrated a unique influence over phage killing of bacteria, whereby, IDANP-exposed bacterial cultures experience 2× the bacterial death as controls. IDANPs consist of hydroxyapatite (HA) doped with iron. HA is a mineral known to be biocompatible and analogous to the inorganic constituent of mammalian bone and teeth and has been approved by the Food and Drug Administration (FDA) for many applications in medicine and dentistry. Previous work has shown that for IDANPs to enhance antibacterial activity of phage to the greatest extent, bacterial cultures should be exposed to IDANPs for 1 hr prior to phage introduction. Biocompatible polymer materials which encase IDANPs and/or phage can be used to disseminate IDANPs and/or phage in a controlled manner into a physiological system for treatment of bacterial infection. When components of said materials contain micro- or nano-scale components, high surface-to-volume ratio for treatment delivery is garnered.

The invention provides freeze-dried nucleated cells, a method for preparing them, and methods of using them for in vitro assays and in vivo therapeutic treatments. The method for preparing the cells includes incubating cells in the presence of a cryoprotective sugar to load them with the sugar, then lyophilizing them without separating the cells from the cryoprotective sugar. In embodiments, the cells are also loaded with one or more bioactive agents.

Bone void filler compositions and methods for preparation to provide substrates with carbonate surface coatings to promote bone growth.

A bioartificial device, such as a bioartificial pancreas, for implantation in a patient's vascular system. The bioartificial pancreas includes a scaffold adapted to engage an interior wall of a blood vessel, a cellular complex support by the scaffold and extending longitudinally within the interior cavity of the scaffold so as to be exposed to the blood flow when the scaffold is engaged with the blood vessel, the cellular complex support comprising one or more pockets bordered by thin film; and cellular complex comprising pancreatic islets disposed in the one or more pockets, the thin film being adapted to permit oxygen and glucose to diffuse from flowing blood into the one or more pockets at a rate sufficient to support the viability of the islets. The invention also includes methods of making and using a bioartificial pancreas.

Biomaterials and methods and uses for repair or augmentation of tissues are provided. In particular, the invention provides a multi-layered, naturally occurring multi-axial oriented biomaterial comprising predominately type I collagen fibers. The invention further provides methods and uses for repair or augmentation of tissues using biomaterials of the invention.

Compliance control stitch patterns sewn or embroidered into biotextile or medical textile substrates impart reinforcing strength, and stretch resistance and control into such substrates. Compliance control stitch patterns may be customizable to particular patients, substrate implantation sites, particular degenerative or diseased conditions, or desired time frames. Substrates having compliance control stitch patterns sewn or embroidered into them may be used in tissue repair or tissue reconstruction applications.

Embodiments of the disclosure include methods and compositions related to repair of weakenings or openings in a tissue of an individual, including at least a muscular wall, for example. In specific cases, a mesh comprising phosphate crosslinked poly(vinyl alcohol) polymer (PVA-P) is utilized for such methods, including for hernia repair of any kind. In particular embodiments, one side of the mesh comprises decellularized gel matrix to provide for enhanced tissue healing.

A human amniotic fluid formulation has been developed for administration into a joint or associated soft tissue such as a tendon or ligament for treatment of pain, degeneration, or injury. The formulation is a sterile de-cellularized human amniotic fluid (D-HAF), devoid of amniotic stem cells and elements of micronized membrane or chorion particles, which has not been heat treated or treated with ethidium bromide. The formulation is optionally diluted, or concentrated, depending on the severity of the disorder or injury. Examples demonstrate efficacy in treatment of pain, disease, disorder, degeneration or injury of a joint or associated soft tissues.

Described are embodiments of a multilaminate or multiple layer implantable surgical graft with an illustrative graft comprising a remodelable collagenous sheet material, the graft including one or more interweaving members to stitch together the graft to help prevent the layers from delaminating or separating during handling and the initial stages of remodeling. The interweaving members may comprise lines of suture, thread, individual stitches, strips of material, etc. that are woven through the layers of biomaterial in a desired pattern. In one embodiment, the interweaving members comprise a pharmacologically active substance, such as a drug, growth factors, etc. to elicit a desired biological response in the host tissue. In another embodiment, the graft further comprises a reinforcing material, such as a synthetic mesh, within the layers of remodelable biomaterial and stitched together by one or more interweaving members.

One aspect of the invention provides a method of preventing or reducing stenosis in a subject. The method includes implanting a passivated graft comprising vein into an artery. The implanting of the graft replaces and/or bypasses a diseased segment of the artery. The passivated graft including vein is prepared by exposing the exterior surface of the passivated graft comprising vein to a tissue structure stabilizing agent (“TSSA”) under conditions sufficient to promote cross-linking of proteins within the vein.